Mike is the Head of Technology and Data Science at F-Prime, where he focuses on opportunities in healthcare technology and data science. Previously Mike worked at Beam Therapeutics, F-Prime, General Motors, and Applied Quantum Technologies.
Mike holds an M.B.A. from the University of Virginia’s Darden School of Business, an M.Eng. in Mechanical Engineering and B.S.E. in Mechanical and Electrical Engineering from Duke University.
Nikhil Ananth is a Principal at F-Prime and invests across multiple subsectors including therapeutics, medical technology, research tools, and life science software & services. Since joining F-Prime in 2019, Nikhil has supported investments in several companies including Adela, Countable Labs, Ensoma, Galatea Bio, Invetx (acquired by Dechra), Ivenix (acquired by Fresenius Kabi), Metsera (NASDAQ: MTSR, acquired by Pfizer), and Rallybio (NASDAQ: RLYB), among others. Nikhil also works closely with the Eight Roads Ventures team to manage F-Prime’s healthcare investments in India.
Prior to joining F-Prime, Nikhil was an Associate at Audax Group in Boston, where he focused on private equity investments in healthcare and software. Nikhil is a graduate of the University of Pennsylvania’s Vagelos Program in Life Sciences & Management, where he received a B.A. in Biology and a B.S. in Economics from the Wharton School.
BioPalette is a life science start up formed out of Kobe University developing base editing technology for a range of applications.
Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs.
Verve Therapeutics (NASDAQ: VERV) is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Verve was acquired by Eli Lilly in 2025.
Connie is a Principal on the life sciences team at F-Prime based in San Francisco. She focuses primarily on biotechnology investments and also works closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Connie joined F-Prime in 2019, and has been involved in a number of company formation efforts including K36 Tx, Skyline, Pediatrix, and AlphaGen. Prior to joining F-Prime, Connie was a Consultant with IQVIA in New York, where she advised biopharmaceutical companies on commercial, development, and portfolio strategy topics.
Connie holds an M.B.A from Harvard Business School, M.S. from the Harvard Department of Stem Cell and Regenerative Biology, and a B.S.E. in Bioengineering from the University of Pennsylvania.
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.
Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including cough, pain, and itch.
Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited.
ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. Specifically, ABK holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the growing field of embolotherapy within the Interventional Radiology/Interventional Oncology medical disciplines. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique, breakthrough embolotherapy products.